Also trades as: 0JDK.L (LSE) · $vol 3M
IOVA NASDAQ
Iovance Biotherapeutics, Inc.
1W: -3.0%
1M: +25.3%
3M: +193.2%
YTD: +446.8%
1Y: +529.2%
3Y: +317.6%
5Y: -46.0%
$14.52
+0.74 (+5.37%)
Weekly Expected Move ±18.3%
$9
$12
$14
$17
$19
Credit Risk of going bust: lower than 52% of companies Debt: 0.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.9%), Iovance Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $46.0M against a stock market value of $6.24B.
Distance to default 5.28 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $23.0M (short-term plus half of long-term), stock volatility 98.3%; Altman Z'' -5.65. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.9%), Iovance Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $46.0M against a stock market value of $6.24B.
Distance to default 5.28 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $23.0M (short-term plus half of long-term), stock volatility 98.3%; Altman Z'' -5.65. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#165
of 1061
Biotechnology
Technical Signal Map
42 Bullish
4 Neutral
75 Bearish
IOVA
$6.4B
Iovance Biotherapeutics, Inc.
BULLISH
+31
LZAGY
$54B
Lonza Group AG
BULLISH
+100
HALO
$14B
Halozyme Therapeutics, Inc.
BULLISH
+100
CAI
$9.1B
Caris Life Sciences, Inc.
BULLISH
+100
MANE
$5.8B
Veradermics, Incorporated
BULLISH
+100
VCEL
$2.2B
Vericel Corporation
BULLISH
+100
LKFT
$2.1B
Lakefront Biotherapeutics N.V.
BULLISH
+100
REGN
$83B
Regeneron Pharmaceuticals, Inc.
BULLISH
+91
ONC
$40B
BeOne Medicines AG
BULLISH
+91
EXEL
$16B
Exelixis, Inc.
BULLISH
+91
ARQT
$3.9B
Arcutis Biotherapeutics, Inc.
BULLISH
+91
BVNRY
$2.9B
Bavarian Nordic A/S
BULLISH
+91
FTRE
$2.2B
Fortrea Holdings Inc.
BULLISH
+91
AGIO
$2.2B
Agios Pharmaceuticals, Inc.
BULLISH
+91
ASND
$15B
Ascendis Pharma A/S
BULLISH
+87
UTHR
$25B
United Therapeutics Corporation
BULLISH
+84
LEGN
$3.6B
Legend Biotech Corporation
BULLISH
+84
VRDN
$2.5B
Viridian Therapeutics, Inc.
BULLISH
+78
AUPH
$2.2B
Aurinia Pharmaceuticals Inc.
BULLISH
+75
BHVN
$2.1B
Biohaven Ltd.
BULLISH
+75
GNMSF
$28B
Genmab A/S
BULLISH
+66
IRON
$2.9B
Disc Medicine, Inc.
BULLISH
+66
NRIX
$2.8B
Nurix Therapeutics, Inc.
BULLISH
+66
ZYME
$2.0B
Zymeworks Inc.
BULLISH
+66
UCBJY
$58B
UCB S.A.
BULLISH
+62
ORKA
$5.3B
Oruka Therapeutics, Inc.
BULLISH
+62
NBIX
$15B
Neurocrine Biosciences, Inc.
BULLISH
+59
KYMR
$9.1B
Kymera Therapeutics, Inc.
BULLISH
+59
ERAS
$5.0B
Erasca, Inc.
BULLISH
+59
CSLLY
$134B
CSL Limited
BULLISH
+58
TECH
$11B
Bio-Techne Corporation
BULLISH
+58
ONTTF
$2.7B
Oxford Nanopore Technologies plc
BULLISH
+56
AKBLF
$7.4B
ALK-Abelló A/S
BULLISH
+53
ADMA
$2.4B
ADMA Biologics, Inc.
BULLISH
+53
ROIV
$26B
Roivant Sciences Ltd.
BULLISH
+50
SYRE
$8.3B
Spyre Therapeutics, Inc.
BULLISH
+42
VRTX
$133B
Vertex Pharmaceuticals Incorporated
BULLISH
+34
LGND
$6.0B
Ligand Pharmaceuticals Incorporated
BULLISH
+33
BBIO
$13B
BridgeBio Pharma, Inc.
LEAN BULL
+27
TGTX
$8.3B
TG Therapeutics, Inc.
LEAN BULL
+26
MRVI
$2.1B
Maravai LifeSciences Holdings, Inc.
LEAN BULL
+26
KOD
$5.5B
Kodiak Sciences Inc.
LEAN BULL
+18
ZLAB
$2.7B
Zai Lab Limited
NEUTRAL
+8
AAVXF
$12B
Abivax S.A.
NEUTRAL
+2
PTGX
$9.0B
Protagonist Therapeutics, Inc.
NEUTRAL
+2
BCHMF
$6.8B
Bachem Holding AG
NEUTRAL
+2
GLPGF
$2.1B
Lakefront Biotherapeutics
LEAN BEAR
-12
MRNA
$80B
Moderna, Inc.
LEAN BEAR
-13
COGT
$5.4B
Cogent Biosciences, Inc.
LEAN BEAR
-15
DFTX
$4.8B
Definium Therapeutics, Inc.
LEAN BEAR
-15
RLAY
$4.0B
Relay Therapeutics, Inc.
LEAN BEAR
-16
ALMR
$2.1B
Alamar Biosciences, Inc.
LEAN BEAR
-19
HNGZY
$6.9B
Hangzhou Tigermed Consulting Co., Ltd
LEAN BEAR
-20
SHJBF
$4.8B
Shanghai Junshi Biosciences Co., Ltd.
LEAN BEAR
-20
CLDX
$2.3B
Celldex Therapeutics, Inc.
LEAN BEAR
-24
SRRK
$5.0B
Scholar Rock Holding Corporation
LEAN BEAR
-27
ELVN
$3.0B
Enliven Therapeutics, Inc.
LEAN BEAR
-27
ARGX
$55B
argenx SE
BEARISH
-35
WXIBF
$26B
WuXi Biologics (Cayman) Inc.
BEARISH
-35
RYTM
$6.2B
Rhythm Pharmaceuticals, Inc.
BEARISH
-35
ACAD
$3.4B
Acadia Pharmaceuticals Inc.
BEARISH
-35
INCY
$23B
Incyte Corporation
BEARISH
-40
EWTX
$4.2B
Edgewise Therapeutics, Inc.
BEARISH
-40
ADPT
$4.1B
Adaptive Biotechnologies Corporation
BEARISH
-40
PHVS
$2.2B
Pharvaris N.V.
BEARISH
-40
SLS
$2.3B
SELLAS Life Sciences Group, Inc.
BEARISH
-42
TNGX
$3.9B
Tango Therapeutics, Inc.
BEARISH
-43
IMNM
$2.1B
Immunome, Inc.
BEARISH
-44
PCVX
$9.5B
Vaxcyte, Inc.
BEARISH
-47
XENE
$3.4B
Xenon Pharmaceuticals Inc.
BEARISH
-49
CELC
$3.2B
Celcuity Inc.
BEARISH
-49
DYN
$2.9B
Dyne Therapeutics, Inc.
BEARISH
-49
IVBXF
$20B
Innovent Biologics, Inc.
BEARISH
-50
BMRN
$11B
BioMarin Pharmaceutical Inc.
BEARISH
-52
GNNSF
$9.6B
Genscript Biotech Corporation
BEARISH
-53
ALNY
$30B
Alnylam Pharmaceuticals, Inc.
BEARISH
-58
MIRM
$5.2B
Mirum Pharmaceuticals, Inc.
BEARISH
-58
TWST
$9.2B
Twist Bioscience Corporation
BEARISH
-59
ABCL
$3.8B
AbCellera Biologics Inc.
BEARISH
-59
CAMRF
$3.7B
Camurus AB
BEARISH
-59
DNTH
$4.3B
Dianthus Therapeutics, Inc.
BEARISH
-60
RCUS
$2.3B
Arcus Biosciences, Inc.
BEARISH
-62
PRAX
$7.1B
Praxis Precision Medicines, Inc.
BEARISH
-65
RVMDW
$40B
Revolution Medicines, Inc. Warrant
BEARISH
-66
BEAM
$2.5B
Beam Therapeutics Inc.
BEARISH
-66
ARWR
$8.2B
Arrowhead Pharmaceuticals, Inc.
BEARISH
-69
IMVT
$5.9B
Immunovant, Inc.
BEARISH
-69
DNLI
$2.9B
Denali Therapeutics Inc.
BEARISH
-74
TXG
$9.3B
10x Genomics, Inc.
BEARISH
-75
BLTE
$5.9B
Belite Bio, Inc
BEARISH
-75
CGON
$5.5B
CG Oncology Inc.
BEARISH
-75
AMLX
$3.4B
Amylyx Pharmaceuticals, Inc.
BEARISH
-75
INCPF
$2.4B
InnoCare Pharma Limited
BEARISH
-75
CYTK
$8.5B
Cytokinetics, Incorporated
BEARISH
-82
VERA
$2.0B
Vera Therapeutics, Inc.
BEARISH
-82
RVMD
$40B
Revolution Medicines, Inc.
BEARISH
-84
BNTX
$22B
BioNTech SE
BEARISH
-84
KRYS
$9.2B
Krystal Biotech, Inc.
BEARISH
-84
CRSP
$4.8B
CRISPR Therapeutics AG
BEARISH
-84
IDYA
$3.4B
IDEAYA Biosciences, Inc.
BEARISH
-84
TARS
$3.2B
Tarsus Pharmaceuticals, Inc.
BEARISH
-84
TLX
$3.1B
Telix Pharmaceuticals Limited
BEARISH
-84
MBX
$2.3B
MBX Biosciences, Inc. Common Stock
BEARISH
-84
PGEN
$2.2B
Precigen, Inc.
BEARISH
-84
JAZZ
$14B
Jazz Pharmaceuticals plc
BEARISH
-87
MDGL
$10B
Madrigal Pharmaceuticals, Inc.
BEARISH
-87
IBRX
$8.7B
ImmunityBio, Inc.
BEARISH
-87
TVTX
$4.7B
Travere Therapeutics, Inc.
BEARISH
-87
BRCTF
$2.6B
BioArctic AB
BEARISH
-87
HRMY
$2.1B
Harmony Biosciences Holdings, Inc.
BEARISH
-87
INSM
$20B
Insmed Incorporated
BEARISH
-91
IONS
$7.1B
Ionis Pharmaceuticals, Inc.
BEARISH
-91
REGMF
$5.6B
RemeGen Co., Ltd.
BEARISH
-91
PTCT
$5.1B
PTC Therapeutics, Inc.
BEARISH
-91
PBLS
$3.0B
Parabilis Medicines, Inc.
BEARISH
-91
NAMS
$2.3B
NewAmsterdam Pharma Company N.V.
BEARISH
-91
SMMT
$12B
Summit Therapeutics Inc.
BEARISH
-100
AXSM
$7.6B
Axsome Therapeutics, Inc.
BEARISH
-100
TRSBF
$4.3B
3SBio Inc.
BEARISH
-100
VKTX
$3.1B
Viking Therapeutics, Inc.
BEARISH
-100
ZLDPF
$2.4B
Zealand Pharma A/S
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -19.3 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 529.2 |
| LZAGY Lonza Group AG | $54B | -409.1 | 13.5 | 10.5 | 17.5 | -9.7 | 8 | BULLISH | 6.2 |
| HALO Halozyme Therapeutics, Inc. | $14B | 36.0 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | BULLISH | 91.4 |
| CAI Caris Life Sciences, Inc. | $9.1B | 86.9 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 2.5 |
| MANE Veradermics, Incorporated | $5.8B | — | — | — | — | — | — | BULLISH | — |
| VCEL Vericel Corporation | $2.2B | 89.8 | 7.2 | 5.9 | 2.8 | 23.0 | 7 | BULLISH | 19.6 |
| LKFT Lakefront Biotherapeutics N.V. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| REGN Regeneron Pharmaceuticals, Inc. | $83B | 19.4 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BULLISH | 40.5 |
| ONC BeOne Medicines AG | $40B | 25.2 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 19.6 |
| EXEL Exelixis, Inc. | $16B | 19.7 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 71.1 |
| ARQT Arcutis Biotherapeutics, Inc. | $3.9B | 144.7 | 15.9 | 34.7 | 11.6 | 76.1 | 7 | BULLISH | 58.4 |
| BVNRY Bavarian Nordic A/S | $2.9B | 12.9 | 12.3 | 7.1 | 36.0 | -5.8 | 7 | BULLISH | -0.2 |
| FTRE Fortrea Holdings Inc. | $2.2B | -25.6 | -15.3 | 0.6 | -1.9 | -2.1 | 6 | BULLISH | 120.7 |
| AGIO Agios Pharmaceuticals, Inc. | $2.2B | -5.2 | -34.3 | -82.5 | -225.1 | 140.6 | 4 | BULLISH | -12.4 |
| ASND Ascendis Pharma A/S | $15B | 18.1 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BULLISH | 22.0 |
| UTHR United Therapeutics Corporation | $25B | 19.3 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 39.1 |
| LEGN Legend Biotech Corporation | $3.6B | -41.1 | -8.1 | -8.2 | 8.6 | 59.5 | 4 | BULLISH | -35.6 |
| VRDN Viridian Therapeutics, Inc. | $2.5B | -6.6 | -65.7 | 418.2 | -44760.2 | 23220.3 | 4 | BULLISH | 5.8 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.2B | 7.2 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BULLISH | 47.1 |
| BHVN Biohaven Ltd. | $2.1B | -3.1 | -799.5 | -1083.0 | — | — | 3 | BULLISH | -11.3 |
| GNMSF Genmab A/S | $28B | 34.9 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 50.6 |
| IRON Disc Medicine, Inc. | $2.9B | -12.1 | -39.1 | 1672.3 | — | — | 1 | BULLISH | -7.2 |
| NRIX Nurix Therapeutics, Inc. | $2.8B | 10.2 | 44.0 | -1896.6 | 81.7 | 738.8 | 8 | BULLISH | 145.5 |
| ZYME Zymeworks Inc. | $2.0B | -14.0 | -72.3 | -156.9 | -980.8 | -69.8 | 2 | BULLISH | 63.0 |
| UCBJY UCB S.A. | $58B | 23.3 | 20.7 | 16.4 | 26.0 | 25.3 | 6 | BULLISH | 5.3 |
| ORKA Oruka Therapeutics, Inc. | $5.3B | -37.6 | -18.2 | -50.3 | — | — | 4 | BULLISH | 232.9 |
| NBIX Neurocrine Biosciences, Inc. | $15B | 20.6 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BULLISH | 1.5 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -35.6 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 98.8 |
| ERAS Erasca, Inc. | $5.0B | -15.7 | -78.2 | -87.5 | — | — | 2 | BULLISH | 578.3 |
| CSLLY CSL Limited | $134B | -26.2 | -15.2 | 13.1 | -40.2 | 1.7 | 4 | BULLISH | -1.5 |
| TECH Bio-Techne Corporation | $11B | 62.1 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | BULLISH | 10.2 |
| ONTTF Oxford Nanopore Technologies plc | $2.7B | -17.4 | -25.6 | -36.2 | -41.1 | 14.4 | 4 | BULLISH | 41.4 |
| AKBLF ALK-Abelló A/S | $7.4B | 39.7 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BULLISH | 12.8 |
| ADMA ADMA Biologics, Inc. | $2.4B | 15.2 | 41.9 | 35.5 | 30.4 | 8.0 | 5 | BULLISH | -27.4 |
| ROIV Roivant Sciences Ltd. | $26B | -95.0 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BULLISH | 99.0 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -48.2 | -23.0 | 359.8 | — | — | 3 | BULLISH | 315.3 |
| VRTX Vertex Pharmaceuticals Incorporated | $133B | 29.7 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BULLISH | 22.4 |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 30.9 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 66.4 |
| BBIO BridgeBio Pharma, Inc. | $13B | -19.2 | 32.4 | 57.9 | -62.5 | 202.4 | 4 | LEAN BULL | 26.6 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.1 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | LEAN BULL | 63.6 |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.1B | -14.2 | -32.9 | 24.4 | -24.1 | -3.3 | 5 | LEAN BULL | 117.8 |
| KOD Kodiak Sciences Inc. | $5.5B | -22.0 | -368.4 | -630.1 | — | — | 1 | LEAN BULL | 423.7 |
| ZLAB Zai Lab Limited | $2.7B | -13.3 | -26.9 | -85.4 | -47.8 | 5.1 | 3 | NEUTRAL | -13.1 |
| AAVXF Abivax S.A. | $12B | -16.7 | -221.8 | 440.6 | — | -133.5 | 4 | NEUTRAL | 57.0 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.7 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | NEUTRAL | 89.7 |
| BCHMF Bachem Holding AG | $6.8B | 41.6 | 10.6 | 8.2 | 15.4 | 4.3 | 3 | NEUTRAL | 24.7 |
| GLPGF Lakefront Biotherapeutics | $2.1B | 3.8 | 20.2 | 39.4 | 17.4 | 259.3 | 5 | LEAN BEAR | -4.5 |
| MRNA Moderna, Inc. | $80B | -23.4 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | LEAN BEAR | 681.3 |
| COGT Cogent Biosciences, Inc. | $5.4B | -13.5 | -109.7 | 1964.0 | — | — | 3 | LEAN BEAR | 108.3 |
| DFTX Definium Therapeutics, Inc. | $4.8B | -10.4 | -25.7 | 82.4 | — | — | 2 | LEAN BEAR | — |
| RLAY Relay Therapeutics, Inc. | $4.0B | -11.7 | -36.8 | -2519.7 | -23916.3 | 23.9 | 4 | LEAN BEAR | 168.1 |
| ALMR Alamar Biosciences, Inc. | $2.1B | — | — | — | — | — | — | LEAN BEAR | — |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 597.8 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | LEAN BEAR | 11.2 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -69.3 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | LEAN BEAR | -20.8 |
| CLDX Celldex Therapeutics, Inc. | $2.3B | -6.8 | -43.9 | -13685.9 | -334104.5 | -98.1 | 1 | LEAN BEAR | 12.3 |
| SRRK Scholar Rock Holding Corporation | $5.0B | -12.5 | -167.8 | 931.3 | — | — | 2 | LEAN BEAR | 45.5 |
| ELVN Enliven Therapeutics, Inc. | $3.0B | -25.8 | -15.3 | -6535.0 | — | — | 3 | LEAN BEAR | 101.9 |
| ARGX argenx SE | $55B | 31.3 | 26.0 | 50.1 | 29.8 | 162.5 | 7 | BEARISH | 7.0 |
| WXIBF WuXi Biologics (Cayman) Inc. | $26B | 31.4 | 10.6 | 16.0 | 20.7 | 16.0 | 9 | BEARISH | 23.1 |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.2B | -29.2 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | BEARISH | -18.0 |
| ACAD Acadia Pharmaceuticals Inc. | $3.4B | 8.9 | 35.7 | 63.9 | 10.2 | 11.8 | 5 | BEARISH | -9.2 |
| INCY Incyte Corporation | $23B | 14.1 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | BEARISH | 26.9 |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | -21.3 | -38.0 | 1912.5 | — | — | 1 | BEARISH | 159.4 |
| ADPT Adaptive Biotechnologies Corporation | $4.1B | -65.1 | -39.6 | -14.1 | -55.6 | 50.1 | 5 | BEARISH | 53.1 |
| PHVS Pharvaris N.V. | $2.2B | -10.6 | -70.7 | 860.9 | — | — | 4 | BEARISH | 37.1 |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | -54.6 | -39.6 | 55646.0 | — | — | 4 | BEARISH | 493.7 |
| TNGX Tango Therapeutics, Inc. | $3.9B | -26.0 | -21.3 | -253.2 | — | 121.5 | 3 | BEARISH | 194.8 |
| IMNM Immunome, Inc. | $2.1B | -7.1 | -64.0 | -2208.4 | — | -100.0 | 4 | BEARISH | 11.4 |
| PCVX Vaxcyte, Inc. | $9.5B | -7.9 | -36.5 | -66.4 | — | — | 0 | BEARISH | 44.2 |
| XENE Xenon Pharmaceuticals Inc. | $3.4B | -7.5 | -43.6 | -109.7 | — | -100.0 | 3 | BEARISH | -13.2 |
| CELC Celcuity Inc. | $3.2B | -15.5 | -1433.7 | 1325.2 | — | — | 3 | BEARISH | -6.8 |
| DYN Dyne Therapeutics, Inc. | $2.9B | -4.9 | -81.6 | 240.4 | — | — | 2 | BEARISH | -4.7 |
| IVBXF Innovent Biologics, Inc. | $20B | 97.0 | 6.9 | 67.2 | 14.5 | 35.4 | 6 | BEARISH | -5.6 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 146.9 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 2.2 |
| GNNSF Genscript Biotech Corporation | $9.6B | -14.1 | -15.4 | 2.9 | -32.0 | 53.1 | 4 | BEARISH | 97.7 |
| ALNY Alnylam Pharmaceuticals, Inc. | $30B | 37.1 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -50.9 |
| MIRM Mirum Pharmaceuticals, Inc. | $5.2B | -5.7 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | BEARISH | 20.0 |
| TWST Twist Bioscience Corporation | $9.2B | -69.7 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | BEARISH | 356.3 |
| ABCL AbCellera Biologics Inc. | $3.8B | -23.0 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | BEARISH | 111.6 |
| CAMRF Camurus AB | $3.7B | 58.0 | 15.8 | 89.3 | 34.3 | -0.2 | 6 | BEARISH | -10.3 |
| DNTH Dianthus Therapeutics, Inc. | $4.3B | -615.5 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | BEARISH | 138.4 |
| RCUS Arcus Biosciences, Inc. | $2.3B | -4.5 | -89.2 | 309.6 | -222.0 | -55.3 | 0 | BEARISH | 5.8 |
| PRAX Praxis Precision Medicines, Inc. | $7.1B | -20.8 | -38.9 | -51.2 | — | -100.0 | 4 | BEARISH | 50.2 |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -20.6 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2279.1 |
| BEAM Beam Therapeutics Inc. | $2.5B | -29.1 | -8.1 | -184.5 | -25036.3 | 158.9 | 4 | BEARISH | -15.6 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.2 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 57.9 |
| IMVT Immunovant, Inc. | $5.9B | -10.1 | -80.1 | 707.5 | -2159.6 | — | 2 | BEARISH | 50.3 |
| DNLI Denali Therapeutics Inc. | $2.9B | -6.6 | -54.9 | -281.7 | -3539.2 | — | 3 | BEARISH | 17.5 |
| TXG 10x Genomics, Inc. | $9.3B | -129.7 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | BEARISH | 446.1 |
| BLTE Belite Bio, Inc | $5.9B | -52.1 | -20.8 | -11.5 | — | — | 3 | BEARISH | 55.4 |
| CGON CG Oncology Inc. | $5.5B | -23.3 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | BEARISH | 46.6 |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.4B | -19.4 | -74.7 | 2020.5 | — | 100.0 | 5 | BEARISH | 89.3 |
| INCPF InnoCare Pharma Limited | $2.4B | 18.7 | 12.6 | 45.8 | 23.1 | 108.5 | 4 | BEARISH | -50.9 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.5 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 5.6 |
| VERA Vera Therapeutics, Inc. | $2.0B | -5.0 | -91.8 | 2030.6 | — | — | 1 | BEARISH | 0.3 |
| RVMD Revolution Medicines, Inc. | $40B | -20.6 | -79.1 | 186.4 | — | — | 1 | BEARISH | 243.7 |
| BNTX BioNTech SE | $22B | -11.4 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -17.1 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.2 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 68.2 |
| CRSP CRISPR Therapeutics AG | $4.8B | -10.4 | -26.1 | -253.2 | -895.3 | -62.7 | 3 | BEARISH | -27.1 |
| IDYA IDEAYA Biosciences, Inc. | $3.4B | -17.2 | -16.2 | -42.9 | -1269.6 | 3244.7 | 4 | BEARISH | 15.7 |
| TARS Tarsus Pharmaceuticals, Inc. | $3.2B | -64.8 | -13.7 | 268.1 | -10.7 | 105.2 | 5 | BEARISH | 2.5 |
| TLX Telix Pharmaceuticals Limited | $3.1B | 92.5 | 8.6 | -1.0 | 8.0 | 10.5 | 4 | BEARISH | -17.4 |
| MBX MBX Biosciences, Inc. Common Stock | $2.3B | -21.3 | -33.2 | 1634.0 | — | — | 2 | BEARISH | 211.8 |
| PGEN Precigen, Inc. | $2.2B | -5.4 | -4640.4 | -30.1 | 36.5 | 1875.0 | 5 | BEARISH | 42.1 |
| JAZZ Jazz Pharmaceuticals plc | $14B | 13.6 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 48.9 |
| MDGL Madrigal Pharmaceuticals, Inc. | $10B | -34.2 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | 3.3 |
| IBRX ImmunityBio, Inc. | $8.7B | -8.5 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 226.8 |
| TVTX Travere Therapeutics, Inc. | $4.7B | -110.7 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 77.5 |
| BRCTF BioArctic AB | $2.6B | 260.2 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BEARISH | -8.6 |
| HRMY Harmony Biosciences Holdings, Inc. | $2.1B | 11.9 | 20.5 | 35.7 | 28.9 | 24.3 | 5 | BEARISH | 24.4 |
| INSM Insmed Incorporated | $20B | -23.1 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -41.7 |
| IONS Ionis Pharmaceuticals, Inc. | $7.1B | -12.5 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | BEARISH | -39.3 |
| REGMF RemeGen Co., Ltd. | $5.6B | 9.1 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | -16.4 |
| PTCT PTC Therapeutics, Inc. | $5.1B | -124.3 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | BEARISH | -8.6 |
| PBLS Parabilis Medicines, Inc. | $3.0B | — | — | — | — | — | — | BEARISH | — |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | -9.1 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -46.2 |
| SMMT Summit Therapeutics Inc. | $12B | -13.2 | -192.5 | 1714.4 | — | — | 3 | BEARISH | -22.7 |
| AXSM Axsome Therapeutics, Inc. | $7.6B | -38.5 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 13.4 |
| TRSBF 3SBio Inc. | $4.3B | 3.4 | 37.1 | 80.3 | 25.3 | 93.8 | 7 | BEARISH | -48.7 |
| VKTX Viking Therapeutics, Inc. | $3.1B | -5.3 | -88.9 | 495.6 | — | — | 1 | BEARISH | -28.6 |
| ZLDPF Zealand Pharma A/S | $2.4B | 5.7 | 16.3 | 57.2 | 87.2 | -49.2 | 3 | BEARISH | -54.1 |
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -19.3 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 529.2 |
| AMRX Amneal Pharmaceuticals, Inc. | $6.5B | 42.7 | -395.8 | 16.0 | 7.2 | 9.3 | 8 | BULLISH | 101.7 |
| TFX Teleflex Incorporated | $5.8B | -5.8 | -28.8 | 1.3 | 17.9 | -14.5 | 5 | BULLISH | 3.8 |
| DOCS Doximity, Inc. | $6.0B | 36.5 | 17.2 | 60.2 | 15.5 | 11.2 | 6 | BULLISH | -50.1 |
| BLCO Bausch + Lomb Corporation | $6.2B | -37.0 | -2.7 | 2.8 | -1.0 | 8.8 | 5 | BULLISH | 11.2 |
| CNVVY ConvaTec Group Plc | $6.3B | 50.8 | 7.6 | 10.2 | 4.4 | 5.5 | 5 | BULLISH | -0.4 |
| LVZPF Livzon Pharmaceutical Group Inc. | $6.1B | 16.0 | 11.5 | 16.4 | 15.3 | -14.4 | 4 | BULLISH | 0.0 |
| GRAL GRAIL Inc. | $5.9B | -15.0 | -16.1 | -24.9 | -246.7 | 23.1 | 5 | BULLISH | 69.3 |
| CHE Chemed Corporation | $6.7B | 25.6 | 27.1 | 23.2 | 10.1 | 3.3 | 6 | BULLISH | 18.1 |
| CHEOY Cochlear Limited | $6.7B | 62.1 | 7.8 | 11.6 | -1.2 | -1.2 | 6 | BULLISH | -47.8 |
| SHTDF Sinopharm Group Co. Ltd. | $6.3B | 6.2 | 8.4 | 8.1 | 1.2 | -2.2 | 5 | LEAN BULL | -18.8 |
| ALBHF Alibaba Health Information Technology Limited | $6.3B | 19.9 | 11.2 | 20.8 | 3.8 | -36.2 | 3 | LEAN BULL | -50.2 |
| SKHHY Sonic Healthcare Limited | $6.5B | 15.5 | 7.3 | 6.2 | 6.2 | 52.7 | 5 | LEAN BULL | -6.3 |
| MSMKF MatsukiyoCocokara & Co. | $5.8B | 18.0 | 11.1 | 12.6 | 5.1 | 5.7 | 8 | NEUTRAL | -16.3 |
| AHICF Asahi Intecc Co., Ltd. | $5.7B | 30.5 | 20.0 | 27.8 | 14.6 | 21.6 | 9 | NEUTRAL | 33.4 |
| DNPUF Sumitomo Pharma Co., Ltd. | $6.4B | 6.9 | 39.1 | 10.3 | 13.1 | 14.5 | 6 | NEUTRAL | 5.6 |
| KNSA Kiniksa Pharmaceuticals International, plc | $6.0B | 59.9 | 14.0 | 51.6 | 10.4 | 58.9 | 7 | BEARISH | 88.2 |
| LNTH Lantheus Holdings, Inc. | $6.5B | 23.8 | 22.2 | 17.1 | 19.3 | 2.3 | 5 | BEARISH | 76.8 |
| YPHDF Ypsomed Holding AG | $5.7B | 23.8 | 31.1 | 17.4 | 22.5 | -2.3 | 8 | BEARISH | -8.1 |
| HIMS Hims & Hers Health, Inc. | $6.2B | -45.5 | -32.0 | -7.1 | -11.5 | 28.0 | 4 | BEARISH | -43.1 |
| SFOSF Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | $5.8B | 17.8 | 10.7 | 6.3 | 8.4 | 53.9 | 7 | BEARISH | -34.2 |
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -19.3 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 529.2 |
| MDT Medtronic Plc | $122B | 23.0 | 10.7 | 7.8 | 15.1 | 9.8 | 9 | BULLISH | 4.0 |
| LZAGY Lonza Group AG | $54B | -409.1 | 13.5 | 10.5 | 17.5 | -9.7 | 8 | BULLISH | 6.2 |
| ORINY Orion Oyj | $30B | 23.1 | 53.6 | 46.3 | 26.9 | 22.6 | 7 | BULLISH | 46.8 |
| RPRX Royalty Pharma plc | $28B | 26.9 | 12.4 | 10.6 | 2.7 | 10.0 | 6 | BULLISH | 76.7 |
| LH Labcorp Holdings Inc. | $27B | 26.9 | 11.7 | 8.6 | 8.0 | 6.4 | 8 | BULLISH | 17.4 |
| ZBH Zimmer Biomet Holdings, Inc. | $19B | 23.2 | 6.4 | 5.9 | 9.1 | 8.6 | 6 | BULLISH | -5.5 |
| MEDP Medpace Holdings, Inc. | $19B | 36.7 | 117.9 | 1953.7 | 19.2 | 20.4 | 9 | BULLISH | 13.4 |
| CRL Charles River Laboratories International, Inc. | $17B | -73.3 | -7.7 | 6.9 | -0.1 | -0.7 | 4 | BULLISH | 87.0 |
| HALO Halozyme Therapeutics, Inc. | $14B | 36.0 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | BULLISH | 91.4 |
| QGEN Qiagen N.V. | $10B | 25.8 | 11.9 | 11.2 | 19.3 | 3.0 | 8 | BULLISH | 2.1 |
| CAI Caris Life Sciences, Inc. | $9.1B | 86.9 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 2.5 |
| RGEDF Chemical Works of Gedeon Richter Plc | $7.4B | 10.6 | 16.2 | 24.3 | 15.9 | 1.8 | 5 | BULLISH | 33.2 |
| ALKS Alkermes plc | $7.3B | 109.6 | 3.9 | 2.9 | 0.1 | 10.8 | 4 | BULLISH | 47.9 |
| AMRX Amneal Pharmaceuticals, Inc. | $6.5B | 42.7 | -395.8 | 16.0 | 7.2 | 9.3 | 8 | BULLISH | 101.7 |
| MANE Veradermics, Incorporated | $5.8B | — | — | — | — | — | — | BULLISH | — |
| TFX Teleflex Incorporated | $5.8B | -5.8 | -28.8 | 1.3 | 17.9 | -14.5 | 5 | BULLISH | 3.8 |
| MMSI Merit Medical Systems, Inc. | $5.6B | 38.2 | 9.2 | 7.3 | 9.3 | 10.2 | 9 | BULLISH | 13.0 |
| CON Concentra Group Holdings Parent, Inc. | $5.0B | 25.7 | 48.5 | 66.4 | 10.8 | 14.0 | 9 | BULLISH | 96.2 |
| LFST LifeStance Health Group, Inc. | $4.9B | 100.0 | 3.4 | 4.1 | 5.4 | 20.4 | 7 | BULLISH | 154.1 |
| ATRC AtriCure, Inc. | $3.0B | 285.0 | 2.2 | 2.9 | 5.8 | 13.9 | 8 | BULLISH | 63.4 |
| GNNDY GN Store Nord A/S | $2.4B | -29.6 | -5.4 | 1.6 | -1.0 | -25.4 | 4 | BULLISH | -7.2 |
| VCEL Vericel Corporation | $2.2B | 89.8 | 7.2 | 5.9 | 2.8 | 23.0 | 7 | BULLISH | 19.6 |
| LKFT Lakefront Biotherapeutics N.V. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| PFE Pfizer Inc. | $171B | 39.3 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.9 |
| DHR Danaher Corporation | $162B | 37.9 | 8.3 | 6.3 | 18.8 | 5.5 | 7 | BULLISH | 5.4 |
| CVS CVS Health Corp. | $120B | 24.2 | 6.2 | 4.9 | 2.8 | 7.4 | 8 | BULLISH | 14.1 |
| MCK McKesson Corporation | $117B | 26.2 | -148.0 | 237.7 | 0.6 | 8.8 | 8 | BULLISH | 25.3 |
| ELV Elevance Health Inc. | $95B | 18.2 | 11.6 | 16.2 | 2.7 | 3.6 | 7 | BULLISH | 25.2 |
| REGN Regeneron Pharmaceuticals, Inc. | $83B | 19.4 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BULLISH | 40.5 |
| CI Cigna Corporation | $81B | 12.5 | 15.5 | 11.8 | 2.3 | 7.7 | 8 | BULLISH | 0.9 |
| TKPHF Takeda Pharmaceutical Company Limited | $66B | 56.1 | 2.5 | 2.8 | 9.3 | 3.3 | 6 | BULLISH | 41.9 |
| CAH Cardinal Health, Inc. | $58B | 34.3 | -60.5 | 92.8 | 0.6 | 14.2 | 8 | BULLISH | 59.6 |
| BDX Becton, Dickinson and Company | $54B | 58.7 | 3.8 | 4.1 | 7.6 | -2.6 | 6 | BULLISH | 5.9 |
| SDZNY Sandoz Group AG | $42B | 66.7 | 7.2 | 10.1 | 1.9 | 29.1 | 6 | BULLISH | 60.0 |
| OTSKY Otsuka Holdings Co., Ltd. | $42B | 16.0 | 13.8 | 12.2 | 16.7 | 10.9 | 8 | BULLISH | 45.1 |
| ONC BeOne Medicines AG | $40B | 25.2 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 19.6 |
| CNC Centene Corp. | $35B | 23.8 | 6.8 | 6.4 | -0.1 | 4.8 | 8 | BULLISH | 98.1 |
| MTD Mettler-Toledo International Inc. | $33B | 37.5 | -736.4 | 46.7 | 22.7 | 6.9 | 8 | BULLISH | 16.2 |
| WST West Pharmaceutical Services, Inc. | $28B | 50.0 | 19.1 | 19.0 | 17.7 | 12.4 | 9 | BULLISH | 28.6 |
| EXEL Exelixis, Inc. | $16B | 19.7 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 71.1 |
| ICLR ICON Public Limited Company | $14B | 42.7 | 3.5 | 5.5 | 3.5 | 2.0 | 6 | BULLISH | 2.1 |
| PMCUF Pro Medicus Limited | $13B | 78.1 | 75.0 | 68.1 | 68.7 | 22.8 | 7 | BULLISH | -30.9 |
| AVTR Avantor, Inc. | $12B | -20.5 | -9.7 | -2.5 | 2.3 | -1.6 | 6 | BULLISH | 11.8 |
| GKOS Glaukos Corporation | $11B | -56.6 | -26.0 | -12.7 | -9.9 | 41.5 | 3 | BULLISH | 137.1 |
| HNGE Hinge Health, Inc. | $9.0B | 82.6 | 30.4 | -235.0 | 20.5 | 417.7 | 7 | BULLISH | 125.4 |
| HQY HealthEquity, Inc. | $8.6B | 36.6 | 11.4 | 9.9 | 18.7 | 7.3 | 8 | BULLISH | 7.7 |
| PACS PACS Group, Inc. | $7.5B | 27.9 | 28.1 | 6.9 | 5.3 | 15.2 | 8 | BULLISH | 282.6 |
| SSMXY Sysmex Corporation | $7.4B | 30.7 | 8.5 | 10.0 | 6.7 | 6.2 | 5 | BULLISH | 4.1 |
| DOCS Doximity, Inc. | $6.0B | 36.5 | 17.2 | 60.2 | 15.5 | 11.2 | 6 | BULLISH | -50.1 |
| WAY Waystar Holding Corp. | $5.5B | 39.3 | 3.8 | 3.8 | 12.8 | 19.2 | 7 | BULLISH | -24.6 |
| HKMPY Hikma Pharmaceuticals PLC | $4.6B | 12.6 | 15.3 | 12.1 | 12.9 | 6.1 | 7 | BULLISH | -3.4 |
| ARQT Arcutis Biotherapeutics, Inc. | $3.9B | 144.7 | 15.9 | 34.7 | 11.6 | 76.1 | 7 | BULLISH | 58.4 |
| ACHC Acadia Healthcare Company, Inc. | $2.9B | -2.5 | -44.5 | 6.1 | 1.3 | 4.3 | 4 | BULLISH | 33.4 |
| BVNRY Bavarian Nordic A/S | $2.9B | 12.9 | 12.3 | 7.1 | 36.0 | -5.8 | 7 | BULLISH | -0.2 |
| BHC Bausch Health Companies Inc. | $2.4B | -2.1 | 86.8 | 12.2 | 9.0 | 10.5 | 5 | BULLISH | -0.3 |
| MD Pediatrix Medical Group, Inc. | $2.4B | 13.6 | 20.4 | 15.9 | 8.2 | 0.5 | 7 | BULLISH | 69.1 |
| FTRE Fortrea Holdings Inc. | $2.2B | -25.6 | -15.3 | 0.6 | -1.9 | -2.1 | 6 | BULLISH | 120.7 |
| PGNY Progyny, Inc. | $2.2B | 28.9 | 16.2 | 30.2 | 8.0 | 5.5 | 7 | BULLISH | 44.3 |
| PRGO Perrigo Company plc | $2.2B | -1.2 | -49.6 | 3.1 | 7.3 | -4.2 | 4 | BULLISH | -24.8 |
| AGIO Agios Pharmaceuticals, Inc. | $2.2B | -5.2 | -34.3 | -82.5 | -225.1 | 140.6 | 4 | BULLISH | -12.4 |
| BOEUF Bonesupport Holding AB (publ) | $2.1B | 79.5 | 29.2 | 54.1 | 22.6 | 23.4 | 8 | BULLISH | 36.7 |
| HCA HCA Healthcare, Inc. | $102B | 54.8 | -124.7 | 23.3 | 8.4 | 7.3 | 6 | BULLISH | 5.7 |
| IDXX IDEXX Laboratories, Inc. | $44B | 39.5 | 74.2 | 46.5 | 27.8 | 12.8 | 9 | BULLISH | -10.7 |
| GEHC GE HealthCare Technologies Inc. | $32B | 20.2 | 15.4 | 10.6 | 10.8 | 1.4 | 5 | BULLISH | -6.8 |
| CLPBY Coloplast A/S | $17B | 38.5 | 18.5 | 70.9 | 19.9 | -2.9 | 5 | BULLISH | -21.7 |
| ASND Ascendis Pharma A/S | $15B | 18.1 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BULLISH | 22.0 |
| PEN Penumbra, Inc. | $13B | 79.4 | 11.4 | 13.6 | 8.9 | 17.6 | 6 | BULLISH | 28.3 |
| SGRY Surgery Partners, Inc. | $2.1B | -33.7 | -5.2 | 5.9 | -1.8 | 4.0 | 5 | BULLISH | 5.8 |
| ABT Abbott Laboratories | $179B | 38.3 | 10.7 | 7.3 | 7.4 | 8.1 | 5 | BULLISH | -17.0 |
| ISRG Intuitive Surgical, Inc. | $160B | 53.8 | 18.0 | 22.6 | 17.1 | 20.5 | 7 | BULLISH | -18.1 |
| SYK Stryker Corporation | $118B | 30.8 | 16.5 | 11.6 | 19.4 | 8.5 | 9 | BULLISH | -20.0 |
| SNY Sanofi | $100B | 23.0 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BULLISH | -15.6 |
| CHGCF Chugai Pharmaceutical Co., Ltd. | $74B | 23.3 | 23.7 | 45.1 | 34.1 | 12.6 | 6 | BULLISH | 1.2 |
| BSX Boston Scientific Corporation | $66B | 18.1 | 15.5 | 11.6 | 16.7 | 13.5 | 8 | BULLISH | -55.5 |
| UTHR United Therapeutics Corporation | $25B | 19.3 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 39.1 |
| PODD Insulet Corp. | $10B | 27.6 | 26.0 | 21.3 | 11.8 | 29.4 | 9 | BULLISH | -53.9 |
| BLCO Bausch + Lomb Corporation | $6.2B | -37.0 | -2.7 | 2.8 | -1.0 | 8.8 | 5 | BULLISH | 11.2 |
| IRTC iRhythm Technologies, Inc. | $4.0B | -281.8 | -9.6 | -3.4 | -0.2 | 25.6 | 6 | BULLISH | -33.1 |
| LEGN Legend Biotech Corporation | $3.6B | -41.1 | -8.1 | -8.2 | 8.6 | 59.5 | 4 | BULLISH | -35.6 |
| WILYY Demant A/S | $12B | 46.7 | 15.9 | 10.9 | 9.1 | 10.6 | 5 | BULLISH | 47.3 |
| HLN Haleon plc | $45B | 20.7 | 10.1 | 8.4 | 13.6 | 1.3 | 8 | BULLISH | 8.9 |
| ZTS Zoetis Inc. | $33B | 13.0 | 64.4 | 26.3 | 28.0 | 1.4 | 6 | BULLISH | -44.5 |
| PHG Koninklijke Philips N.V. | $26B | 20.3 | 10.2 | 7.6 | 8.8 | -1.1 | 6 | BULLISH | -8.4 |
| SNN Smith & Nephew plc | $13B | 19.8 | 11.8 | 9.9 | 9.8 | 5.3 | 7 | BULLISH | -14.2 |
| COO The Cooper Companies, Inc. | $12B | 20.4 | 6.8 | 6.3 | 40.6 | 4.7 | 6 | BULLISH | -17.9 |
| VRDN Viridian Therapeutics, Inc. | $2.5B | -6.6 | -65.7 | 418.2 | -44760.2 | 23220.3 | 4 | BULLISH | 5.8 |
| ESLOF EssilorLuxottica S.A. | $94B | 33.2 | 6.5 | 5.2 | 10.6 | 7.4 | 6 | BULLISH | -44.7 |
| SOAGY Sartorius AG ADR | $92B | 90.9 | 7.7 | 6.6 | 7.1 | 4.3 | 7 | BULLISH | 18.0 |
| EW Edwards Lifesciences Corporation | $51B | 51.7 | 9.5 | 17.9 | 13.9 | 14.6 | 6 | BULLISH | 18.3 |
| BIIB Biogen Inc. | $37B | 44.2 | 4.6 | 4.8 | 3.6 | -0.5 | 3 | BULLISH | 68.1 |
| TRUMY Terumo Corporation | $22B | 21.5 | 11.0 | 9.6 | 22.6 | 15.6 | 5 | BULLISH | -8.5 |
| ALGN Align Technology, Inc. | $11B | 26.3 | 10.2 | 12.3 | 10.3 | 4.4 | 7 | BULLISH | 12.0 |
| HTFL Heartflow, Inc. Common Stock | $4.9B | -40.4 | -42.3 | -39.8 | -24.6 | — | 2 | BULLISH | 42.9 |
| DSRLF DiaSorin S.p.A. | $4.4B | 25.0 | 14.2 | 8.9 | 14.0 | 46.3 | 5 | BULLISH | -2.4 |
| VCYT Veracyte, Inc. | $3.9B | 33.6 | 8.8 | 10.7 | 17.0 | 17.3 | 8 | BULLISH | 35.2 |
| PLSE Pulse Biosciences, Inc. | $3.8B | -45.2 | -78.5 | -1410.2 | -5681.3 | — | 3 | BULLISH | 202.6 |
| CZMWY Carl Zeiss Meditec AG | $3.5B | 21.2 | 5.6 | 4.8 | 9.8 | 22.1 | 7 | BULLISH | -28.0 |
| AVAH Aveanna Healthcare Holdings Inc. | $2.9B | 9.8 | 199.1 | 30.4 | 6.0 | 20.3 | 6 | BULLISH | 44.5 |
| SZUKF Suzuken Co., Ltd. | $2.4B | 10.9 | 9.3 | 8.6 | 0.5 | 5.0 | 4 | BULLISH | 18.9 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.2B | 7.2 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BULLISH | 47.1 |
| BHVN Biohaven Ltd. | $2.1B | -3.1 | -799.5 | -1083.0 | — | — | 3 | BULLISH | -11.3 |
| NTRA Natera, Inc. | $58B | -297.1 | -12.5 | -23.6 | -8.9 | 37.8 | 6 | BULLISH | 107.6 |
| MKGAF Merck KGaA | $70B | 26.1 | 8.1 | 8.1 | 9.0 | -0.4 | 7 | BULLISH | 24.1 |
| COR Cencora, Inc. | $63B | 24.2 | 104.3 | 26.5 | 0.9 | 5.1 | 7 | BULLISH | 0.7 |
| IQV IQVIA Holdings Inc. | $46B | 33.0 | 21.7 | 33.3 | 7.9 | 8.8 | 9 | BULLISH | 24.4 |
| WAT Waters Corporation | $45B | 114.0 | 1.9 | 1.5 | -8.3 | 52.5 | 5 | BULLISH | 28.2 |
| GNMSF Genmab A/S | $28B | 34.9 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 50.6 |
| SONVF Sonova Holding AG | $20B | 38.9 | 20.4 | 17.2 | 19.7 | -7.1 | 6 | BULLISH | 22.9 |
| BAX Baxter International Inc. | $13B | -12.2 | -15.7 | -1.6 | 4.3 | 5.4 | 3 | BULLISH | 10.2 |
| GNGBY Getinge AB (publ) | $7.3B | 25.9 | 9.1 | 8.1 | 8.5 | -3.9 | 7 | BULLISH | 13.2 |
| HLUBF H. Lundbeck A/S | $7.3B | 13.4 | 15.2 | 12.6 | 17.6 | 10.1 | 7 | BULLISH | 22.5 |
| CNVVY ConvaTec Group Plc | $6.3B | 50.8 | 7.6 | 10.2 | 4.4 | 5.5 | 5 | BULLISH | -0.4 |
| MAHLY MediPal Holdings Corporation | $4.1B | 15.1 | 7.5 | 8.7 | 1.4 | 5.9 | 7 | BULLISH | 23.9 |
| IRON Disc Medicine, Inc. | $2.9B | -12.1 | -39.1 | 1672.3 | — | — | 1 | BULLISH | -7.2 |
| NRIX Nurix Therapeutics, Inc. | $2.8B | 10.2 | 44.0 | -1896.6 | 81.7 | 738.8 | 8 | BULLISH | 145.5 |
| ZYME Zymeworks Inc. | $2.0B | -14.0 | -72.3 | -156.9 | -980.8 | -69.8 | 2 | BULLISH | 63.0 |
| UCBJY UCB S.A. | $58B | 23.3 | 20.7 | 16.4 | 26.0 | 25.3 | 6 | BULLISH | 5.3 |
| ALC Alcon Inc. | $34B | 53.5 | 2.9 | 3.6 | 0.0 | 7.8 | 6 | BULLISH | -8.2 |
| STE STERIS plc | $23B | 27.9 | 11.4 | 9.7 | 13.4 | 8.4 | 8 | BULLISH | -4.6 |
| LVZPF Livzon Pharmaceutical Group Inc. | $6.1B | 16.0 | 11.5 | 16.4 | 15.3 | -14.4 | 4 | BULLISH | 0.0 |
| ORKA Oruka Therapeutics, Inc. | $5.3B | -37.6 | -18.2 | -50.3 | — | — | 4 | BULLISH | 232.9 |
| GSK GSK plc | $102B | 16.0 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | BULLISH | 13.2 |
| SEMHF Siemens Healthineers AG | $53B | 21.2 | 12.1 | 8.4 | 11.6 | 10.0 | 9 | BULLISH | -17.7 |
| DGX Quest Diagnostics Incorporated | $27B | 23.6 | 15.2 | 10.2 | 10.1 | 9.1 | 8 | BULLISH | 32.6 |
| SAUHY Straumann Holding AG | $19B | 41.8 | 17.3 | 21.7 | 18.1 | 3.0 | 6 | BULLISH | 5.1 |
| NBIX Neurocrine Biosciences, Inc. | $15B | 20.6 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BULLISH | 1.5 |
| GMED Globus Medical, Inc. | $11B | 20.2 | 11.8 | 12.3 | 19.2 | 19.7 | 8 | BULLISH | 30.2 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -35.6 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 98.8 |
| OPHLY Ono Pharmaceutical Co., Ltd. | $7.4B | 15.2 | 9.5 | 11.3 | 20.8 | 3.3 | 9 | BULLISH | 32.7 |
| ERAS Erasca, Inc. | $5.0B | -15.7 | -78.2 | -87.5 | — | — | 2 | BULLISH | 578.3 |
| LIVN LivaNova PLC | $4.4B | 23.3 | 15.4 | 30.2 | 27.8 | 12.4 | 8 | BULLISH | 48.1 |
| SNPHY Santen Pharmaceutical Co., Ltd. | $3.6B | 14.7 | 13.6 | 14.9 | 10.4 | 0.9 | 8 | BULLISH | 10.7 |
| CSLLY CSL Limited | $134B | -26.2 | -15.2 | 13.1 | -40.2 | 1.7 | 4 | BULLISH | -1.5 |
| RVTY Revvity, Inc. | $18B | 76.0 | 3.2 | 3.5 | 7.1 | 5.5 | 6 | BULLISH | 64.4 |
| TECH Bio-Techne Corporation | $11B | 62.1 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | BULLISH | 10.2 |
| MOH Molina Healthcare, Inc. | $11B | -329.7 | -1.2 | -44.2 | 0.4 | -2.1 | 5 | BULLISH | 27.3 |
| MTHRY M3, Inc. | $8.2B | 27.5 | 12.1 | 16.9 | 10.1 | 17.7 | 7 | BULLISH | -16.9 |
| HAE Haemonetics Corporation | $5.4B | 57.8 | 11.2 | 10.1 | 9.7 | 0.4 | 8 | BULLISH | 132.2 |
| CDNA CareDx, Inc | $3.6B | 32.7 | 29.5 | -2.5 | 83.8 | 34.4 | 8 | BULLISH | 370.1 |
| ONTTF Oxford Nanopore Technologies plc | $2.7B | -17.4 | -25.6 | -36.2 | -41.1 | 14.4 | 4 | BULLISH | 41.4 |
| ESAIY Eisai Co., Ltd. | $9.2B | 34.0 | 3.8 | 3.3 | 7.8 | 248.0 | 6 | BULLISH | 9.2 |
| ATR AptarGroup, Inc. | $8.1B | 22.6 | 13.6 | 10.1 | 8.5 | 8.9 | 6 | BULLISH | -2.8 |
| AKBLF ALK-Abelló A/S | $7.4B | 39.7 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BULLISH | 12.8 |
| OPCH Option Care Health, Inc. | $4.7B | 23.5 | 16.0 | 10.6 | 3.7 | 5.9 | 5 | BULLISH | 11.4 |
| AMBBY Ambu A/S | $3.2B | 41.7 | 8.5 | 9.0 | 9.5 | -411.9 | 6 | BULLISH | -28.5 |
| PRVA Privia Health Group, Inc. | $2.9B | 97.6 | 0.0 | 0.0 | 1.4 | 24.1 | 1 | BULLISH | -14.4 |
| ADMA ADMA Biologics, Inc. | $2.4B | 15.2 | 41.9 | 35.5 | 30.4 | 8.0 | 5 | BULLISH | -27.4 |
| DRWKF Drägerwerk AG & Co. KGaA | $2.3B | 11.1 | 11.0 | 9.8 | 3.5 | 6.5 | 9 | BULLISH | 36.8 |
| IPSEY Ipsen S.A. | $58B | 24.4 | 11.5 | 16.3 | 18.2 | 8.0 | 6 | BULLISH | 25.4 |
| GILD Gilead Sciences, Inc. | $193B | -60.6 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 32.3 |
| DSNKY Daiichi Sankyo Company, Limited | $33B | 19.6 | 15.1 | 12.5 | 11.9 | 17.4 | 5 | BULLISH | -33.2 |
| ROIV Roivant Sciences Ltd. | $26B | -95.0 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BULLISH | 99.0 |
| VTRS Viatris Inc. | $21B | -51.7 | -2.8 | -0.3 | -3.2 | 4.4 | 7 | BULLISH | 79.5 |
| BMXXY bioMérieux S.A. | $12B | 22.6 | 11.2 | 8.9 | 11.5 | -3.5 | 7 | BULLISH | -28.0 |
| DVA DaVita Inc. | $12B | 15.7 | -149.4 | 17.9 | 7.5 | 6.4 | 8 | BULLISH | 43.8 |
| UHS Universal Health Services, Inc. | $11B | 7.2 | 21.0 | 12.5 | 7.7 | 10.0 | 8 | BULLISH | -10.8 |
| RDY Dr. Reddy's Laboratories Limited | $11B | 39.0 | 7.5 | 6.0 | 10.7 | -3.1 | 4 | BULLISH | -5.9 |
| HUM Humana Inc. | $51B | 39.2 | 6.8 | 17.2 | 1.7 | 18.3 | 4 | BULLISH | 43.1 |
| TCHBF Tecan Group AG | $3.5B | -26.4 | -9.7 | 2.8 | 2.9 | -4.2 | 6 | BULLISH | 45.2 |
| RCDTF Recordati Industria Chimica e Farmaceutica S.p.A. | $12B | 21.8 | 24.9 | 15.4 | 16.7 | 9.2 | 7 | BULLISH | -9.2 |
| GRAL GRAIL Inc. | $5.9B | -15.0 | -16.1 | -24.9 | -246.7 | 23.1 | 5 | BULLISH | 69.3 |
| EKTAY Elekta AB (publ) | $2.2B | -61.1 | -4.4 | -49.1 | 7.5 | -7.8 | 4 | BULLISH | 8.0 |
| FSNUY Fresenius SE & Co. KGaA | $117B | 16.8 | 8.1 | 5.6 | 6.4 | 5.9 | 7 | BULLISH | -18.2 |
| ENSG The Ensign Group, Inc. | $10B | 26.2 | 17.0 | 8.1 | 6.9 | 18.9 | 7 | BULLISH | -4.6 |
| BLLN BillionToOne, Inc. | $5.1B | 161.6 | 6.0 | 25.2 | 7.4 | — | 4 | BULLISH | — |
| THC Tenet Healthcare Corporation | $22B | 9.8 | 53.3 | 19.1 | 14.7 | 5.4 | 7 | BULLISH | 30.0 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -48.2 | -23.0 | 359.8 | — | — | 3 | BULLISH | 315.3 |
| ERFSF Eurofins Scientific SE | $17B | 28.5 | 12.8 | 4.6 | 8.2 | 3.3 | 6 | BULLISH | 33.0 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $16B | 60.2 | 23.3 | 27.3 | 20.6 | 5.0 | 6 | BULLISH | 45.1 |
| ICUI ICU Medical, Inc. | $4.2B | 137.6 | 1.4 | 2.7 | 3.5 | -9.0 | 6 | BULLISH | 36.4 |
| ADUS Addus HomeCare Corporation | $2.3B | 21.3 | 9.7 | 9.6 | 7.3 | 15.9 | 6 | BULLISH | 0.4 |
| EHC Encompass Health Corporation | $12B | 19.5 | 25.5 | 16.7 | 9.6 | 9.5 | 9 | BULLISH | -1.8 |
| LQDA Liquidia Corporation | $3.8B | 28.2 | 131.8 | 391.9 | 43.5 | 2233.6 | 6 | BULLISH | 98.6 |
| VRTX Vertex Pharmaceuticals Incorporated | $133B | 29.7 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BULLISH | 22.4 |
| SGIOY Shionogi & Co., Ltd. | $16B | 9.8 | 13.6 | 9.9 | 50.6 | 10.3 | 5 | BULLISH | 20.9 |
| RGEN Repligen Corporation | $11B | -823.9 | -0.6 | -1.4 | -18.4 | 13.8 | 4 | BULLISH | 9.0 |
| CHEOY Cochlear Limited | $6.7B | 62.1 | 7.8 | 11.6 | -1.2 | -1.2 | 6 | BULLISH | -47.8 |
| CHE Chemed Corporation | $6.7B | 25.6 | 27.1 | 23.2 | 10.1 | 3.3 | 6 | BULLISH | 18.1 |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 30.9 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 66.4 |
| APNHY Aspen Pharmacare Holdings Limited | $4.2B | 26.8 | 3.2 | 5.3 | 6.6 | -20.1 | 7 | BULLISH | 69.4 |
| ALPMF Astellas Pharma Inc. | $30B | 12.4 | 21.4 | 16.9 | 22.1 | 17.3 | 7 | BULLISH | 65.7 |
| HCM HUTCHMED (China) Limited | $2.6B | 149.4 | 46.6 | 11.0 | 5.7 | -11.8 | 6 | BULLISH | -5.1 |
| ILMN Illumina, Inc. | $41B | 51.2 | 32.4 | 18.2 | 17.9 | 4.9 | 7 | LEAN BULL | 171.1 |
| BBIO BridgeBio Pharma, Inc. | $13B | -19.2 | 32.4 | 57.9 | -62.5 | 202.4 | 4 | LEAN BULL | 26.6 |
| SHC Sotera Health Company | $5.2B | 32.1 | 27.8 | 10.6 | 16.7 | 8.1 | 7 | LEAN BULL | 8.8 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.1 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | LEAN BULL | 63.6 |
| SHTDF Sinopharm Group Co. Ltd. | $6.3B | 6.2 | 8.4 | 8.1 | 1.2 | -2.2 | 5 | LEAN BULL | -18.8 |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.1B | -14.2 | -32.9 | 24.4 | -24.1 | -3.3 | 5 | LEAN BULL | 117.8 |
| A Agilent Technologies, Inc. | $49B | 34.6 | 21.0 | 14.9 | 19.3 | 8.6 | 7 | LEAN BULL | 19.3 |
| SDGCF Sundrug Co.,Ltd. | $3.3B | 13.5 | 11.4 | 10.6 | 3.7 | 4.9 | 6 | LEAN BULL | 0.0 |
| ARHCF Alfresa Holdings Corporation | $2.5B | 11.4 | 5.7 | 7.8 | 0.2 | 3.6 | 5 | LEAN BULL | 17.9 |
| INSP Inspire Medical Systems, Inc. | $2.1B | 15.0 | 18.0 | 19.7 | 0.2 | 4.3 | 8 | LEAN BULL | -11.4 |
| OSCR Oscar Health, Inc. | $8.0B | 18.4 | 34.3 | -9.6 | 7.4 | 42.8 | 7 | LEAN BULL | 58.5 |
| HOCPY HOYA Corporation | $56B | 33.4 | 27.3 | 46.1 | 25.7 | 14.2 | 6 | LEAN BULL | 10.1 |
| BIO Bio-Rad Laboratories, Inc. | $9.9B | 45.0 | 3.1 | 2.2 | 57.1 | 1.4 | 7 | LEAN BULL | 10.1 |
| KOD Kodiak Sciences Inc. | $5.5B | -22.0 | -368.4 | -630.1 | — | — | 1 | LEAN BULL | 423.7 |
| NVST Envista Holdings Corp | $3.8B | 40.1 | 3.1 | 3.2 | 7.4 | 11.9 | 7 | LEAN BULL | 17.0 |
| BMY Bristol-Myers Squibb Company | $126B | 13.5 | 46.7 | 17.8 | 25.6 | 3.1 | 8 | LEAN BULL | 46.8 |
| TEVA Teva Pharmaceutical Industries Limited | $46B | 64.1 | 9.7 | 9.3 | -13.9 | 4.1 | 7 | LEAN BULL | 110.1 |
| BIOVF Swedish Orphan Biovitrum AB | $16B | 115.7 | 3.4 | 17.2 | 14.0 | 13.3 | 4 | LEAN BULL | 37.3 |
| PBH Prestige Consumer Healthcare Inc. | $2.3B | 13.0 | 9.1 | 5.5 | 11.0 | -1.4 | 4 | LEAN BULL | -23.0 |
| SKHHY Sonic Healthcare Limited | $6.5B | 15.5 | 7.3 | 6.2 | 6.2 | 52.7 | 5 | LEAN BULL | -6.3 |
| ALBHF Alibaba Health Information Technology Limited | $6.3B | 19.9 | 11.2 | 20.8 | 3.8 | -36.2 | 3 | LEAN BULL | -50.2 |
| GH Guardant Health, Inc. | $23B | -49.9 | 171.6 | -88.3 | -35.9 | 42.7 | 6 | LEAN BULL | 149.8 |
| NEOG Neogen Corporation | $2.7B | -49.4 | -2.7 | -0.2 | -5.3 | -0.3 | 7 | LEAN BULL | 101.2 |
| FMS Fresenius Medical Care AG & Co. KGaA | $12B | 12.2 | 7.3 | 6.7 | 4.5 | -0.5 | 7 | NEUTRAL | -15.4 |
| BRKR Bruker Corporation | $8.8B | -83.6 | -3.4 | 3.0 | -6.2 | 1.6 | 6 | NEUTRAL | 46.8 |
| MSMKF MatsukiyoCocokara & Co. | $5.8B | 18.0 | 11.1 | 12.6 | 5.1 | 5.7 | 8 | NEUTRAL | -16.3 |
| ZLAB Zai Lab Limited | $2.7B | -13.3 | -26.9 | -85.4 | -47.8 | 5.1 | 3 | NEUTRAL | -13.1 |
| KYKOF Kyowa Kirin Co., Ltd. | $8.1B | 15.6 | 9.3 | 14.2 | 12.8 | 7.4 | 7 | NEUTRAL | -8.1 |
| ITGR Integer Holdings Corporation | $4.3B | 34.3 | 7.5 | 5.4 | 5.1 | 2.6 | 7 | NEUTRAL | 71.3 |
| AAVXF Abivax S.A. | $12B | -16.7 | -221.8 | 440.6 | — | -133.5 | 4 | NEUTRAL | 57.0 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.7 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | NEUTRAL | 89.7 |
| BCHMF Bachem Holding AG | $6.8B | 41.6 | 10.6 | 8.2 | 15.4 | 4.3 | 3 | NEUTRAL | 24.7 |
| AHICF Asahi Intecc Co., Ltd. | $5.7B | 30.5 | 20.0 | 27.8 | 14.6 | 21.6 | 9 | NEUTRAL | 33.4 |
| BUHPF Bumrungrad Hospital Public Company Limited | $4.8B | 21.0 | 27.3 | 37.3 | 30.3 | 1.6 | 5 | NEUTRAL | 23.7 |
| ANSLY Ansell Limited | $4.7B | 22.3 | 10.6 | 9.5 | 10.8 | 7.1 | 8 | NEUTRAL | 43.8 |
| CSMYF COSMOS Pharmaceutical Corporation | $3.2B | 15.6 | 11.7 | 9.8 | 2.9 | 9.5 | 6 | NEUTRAL | -12.2 |
| JDHIY JD Health International Inc. | $16B | 16.4 | 10.3 | 31.0 | 8.4 | 19.6 | 6 | NEUTRAL | -43.9 |
| CHJTF CSPC Pharmaceutical Group Limited | $14B | 10.3 | 20.7 | 36.7 | 32.8 | 88.1 | 6 | NEUTRAL | 13.3 |
| TSUSF Tsuruha Holdings Inc. | $4.2B | 17.4 | 6.2 | 12.0 | 2.8 | 16.1 | 5 | NEUTRAL | 56.8 |
| NONOF Novo Nordisk A/S | $172B | 9.9 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | NEUTRAL | -28.1 |
| IHHHF IHH Healthcare Berhad | $15B | 30.9 | 7.3 | 6.1 | 8.1 | 7.1 | 5 | NEUTRAL | 43.7 |
| DNPUF Sumitomo Pharma Co., Ltd. | $6.4B | 6.9 | 39.1 | 10.3 | 13.1 | 14.5 | 6 | NEUTRAL | 5.6 |
| SGFEF Siegfried Holding AG | $3.9B | 19.0 | 17.0 | 9.4 | 10.8 | 3.4 | 4 | NEUTRAL | -15.8 |
| AXGN AxoGen, Inc. | $2.2B | -55.9 | -18.2 | -5.6 | -2.2 | 23.6 | 4 | NEUTRAL | 110.6 |
| BTSG BrightSpring Health Services, Inc. Common Stock | $12B | 41.0 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 75.8 |
| GEDSF Gedeon Richter PLC | $4.5B | 10.6 | 16.4 | 22.0 | 29.6 | 4.8 | 7 | LEAN BEAR | 0.0 |
| GLPGF Lakefront Biotherapeutics | $2.1B | 3.8 | 20.2 | 39.4 | 17.4 | 259.3 | 5 | LEAN BEAR | -4.5 |
| MRNA Moderna, Inc. | $80B | -23.4 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | LEAN BEAR | 681.3 |
| RDNT RadNet, Inc. | $5.5B | -278.6 | -2.1 | 1.8 | 1.2 | 18.9 | 5 | LEAN BEAR | -15.5 |
| COGT Cogent Biosciences, Inc. | $5.4B | -13.5 | -109.7 | 1964.0 | — | — | 3 | LEAN BEAR | 108.3 |
| STVN Stevanato Group S.p.A. | $5.3B | 36.7 | 9.1 | 7.2 | 7.6 | 6.7 | 6 | LEAN BEAR | -28.0 |
| DFTX Definium Therapeutics, Inc. | $4.8B | -10.4 | -25.7 | 82.4 | — | — | 2 | LEAN BEAR | — |
| SUVPF Sartorius AG | $19B | 90.9 | 7.7 | 6.7 | 7.1 | 3.6 | 7 | LEAN BEAR | 8.9 |
| RLAY Relay Therapeutics, Inc. | $4.0B | -11.7 | -36.8 | -2519.7 | -23916.3 | 23.9 | 4 | LEAN BEAR | 168.1 |
| ALMR Alamar Biosciences, Inc. | $2.1B | — | — | — | — | — | — | LEAN BEAR | — |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 597.8 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | LEAN BEAR | 11.2 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -69.3 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | LEAN BEAR | -20.8 |
| MCVEF Medicover AB (publ) | $4.1B | 44.4 | 16.9 | 6.8 | 3.8 | 9.4 | 7 | LEAN BEAR | 0.0 |
| CLDX Celldex Therapeutics, Inc. | $2.3B | -6.8 | -43.9 | -13685.9 | -334104.5 | -98.1 | 1 | LEAN BEAR | 12.3 |
| PTKFF PT Kalbe Farma Tbk. | $2.0B | 8.9 | 15.4 | 17.6 | 9.1 | 13.2 | 5 | LEAN BEAR | -18.5 |
| RSMDF ResMed Inc. | $36B | 23.9 | 24.3 | 25.3 | 26.2 | 9.9 | 7 | LEAN BEAR | -8.5 |
| OGN Organon & Co. | $3.6B | 17.4 | 24.0 | 6.0 | 6.9 | -2.5 | 5 | LEAN BEAR | 52.4 |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | $12B | 41.0 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 70.4 |
| SRRK Scholar Rock Holding Corporation | $5.0B | -12.5 | -167.8 | 931.3 | — | — | 2 | LEAN BEAR | 45.5 |
| ELVN Enliven Therapeutics, Inc. | $3.0B | -25.8 | -15.3 | -6535.0 | — | — | 3 | LEAN BEAR | 101.9 |
| UFPT UFP Technologies, Inc. | $2.3B | 31.2 | 17.1 | 13.3 | 12.0 | 7.3 | 7 | LEAN BEAR | 45.5 |
| GALNF Galenica AG | $5.0B | 27.6 | 11.2 | 6.8 | 3.1 | 6.2 | 4 | BEARISH | 32.2 |
| ELAN Elanco Animal Health Incorporated | $11B | -55.9 | -3.0 | 3.7 | 3.9 | 12.0 | 5 | BEARISH | 5.5 |
| HSIC Henry Schein, Inc. | $9.5B | 24.3 | 12.2 | 8.7 | 2.7 | 6.5 | 7 | BEARISH | 32.9 |
| INDV Indivior Pharmaceuticals Inc | $4.3B | 12.0 | -152.4 | 528.3 | 35.6 | 13.5 | 4 | BEARISH | 36.7 |
| NEO NeoGenomics, Inc. | $2.2B | -42.8 | -6.3 | -4.8 | 1.1 | 11.2 | 5 | BEARISH | 59.7 |
| ARGX argenx SE | $55B | 31.3 | 26.0 | 50.1 | 29.8 | 162.5 | 7 | BEARISH | 7.0 |
| WXIBF WuXi Biologics (Cayman) Inc. | $26B | 31.4 | 10.6 | 16.0 | 20.7 | 16.0 | 9 | BEARISH | 23.1 |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.2B | -29.2 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | BEARISH | -18.0 |
| ACAD Acadia Pharmaceuticals Inc. | $3.4B | 8.9 | 35.7 | 63.9 | 10.2 | 11.8 | 5 | BEARISH | -9.2 |
| PANHF Ping An Healthcare and Technology Company Limited | $2.1B | 20.7 | 4.6 | 5.6 | 8.8 | 2.9 | 6 | BEARISH | -61.7 |
| CLOV Clover Health Investments, Corp. | $2.4B | -113.1 | -5.1 | -8.3 | 3.8 | 54.0 | 4 | BEARISH | 42.5 |
| BAYRY Bayer AG | $48B | -25.8 | -5.5 | 6.4 | 2.0 | -1.5 | 4 | BEARISH | 59.4 |
| INCY Incyte Corporation | $23B | 14.1 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | BEARISH | 26.9 |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | -21.3 | -38.0 | 1912.5 | — | — | 1 | BEARISH | 159.4 |
| ADPT Adaptive Biotechnologies Corporation | $4.1B | -65.1 | -39.6 | -14.1 | -55.6 | 50.1 | 5 | BEARISH | 53.1 |
| RGC Regencell Bioscience Holdings Limited | $3.8B | -283.1 | -128.5 | 1692.4 | — | — | 3 | BEARISH | -57.8 |
| CLCGY Clicks Group Limited | $3.1B | 16.0 | 47.7 | 39.1 | 6.5 | 6.3 | 6 | BEARISH | -37.6 |
| PHVS Pharvaris N.V. | $2.2B | -10.6 | -70.7 | 860.9 | — | — | 4 | BEARISH | 37.1 |
| ALVOW Alvotech | $3.9B | -7.9 | 98.5 | 3.3 | -63.2 | -12.2 | 0 | BEARISH | -84.6 |
| SOLV Solventum Corporation | $15B | 10.1 | 34.0 | 18.1 | 4.2 | -0.9 | 7 | BEARISH | 18.8 |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | -54.6 | -39.6 | 55646.0 | — | — | 4 | BEARISH | 493.7 |
| TNGX Tango Therapeutics, Inc. | $3.9B | -26.0 | -21.3 | -253.2 | — | 121.5 | 3 | BEARISH | 194.8 |
| NHNKY Nihon Kohden Corporation | $3.1B | 19.1 | 7.8 | 7.9 | -1.6 | 2.6 | 9 | BEARISH | -22.6 |
| GRDN Guardian Pharmacy Services, Inc. | $2.5B | 37.4 | 31.7 | 33.2 | 6.2 | 10.3 | 7 | BEARISH | 39.9 |
| IMNM Immunome, Inc. | $2.1B | -7.1 | -64.0 | -2208.4 | — | -100.0 | 4 | BEARISH | 11.4 |
| PCVX Vaxcyte, Inc. | $9.5B | -7.9 | -36.5 | -66.4 | — | — | 0 | BEARISH | 44.2 |
| BDULF Bangkok Dusit Medical Services Public Company Limited | $9.7B | 20.7 | 15.0 | 12.4 | 12.1 | 1.3 | 4 | BEARISH | -3.2 |
| XENE Xenon Pharmaceuticals Inc. | $3.4B | -7.5 | -43.6 | -109.7 | — | -100.0 | 3 | BEARISH | -13.2 |
| CELC Celcuity Inc. | $3.2B | -15.5 | -1433.7 | 1325.2 | — | — | 3 | BEARISH | -6.8 |
| DYN Dyne Therapeutics, Inc. | $2.9B | -4.9 | -81.6 | 240.4 | — | — | 2 | BEARISH | -4.7 |
| IVBXF Innovent Biologics, Inc. | $20B | 97.0 | 6.9 | 67.2 | 14.5 | 35.4 | 6 | BEARISH | -5.6 |
| RADLY Raia Drogasil S.A. | $7.2B | 21.1 | 19.4 | 16.9 | 3.8 | 10.9 | 7 | BEARISH | -21.9 |
| KNSA Kiniksa Pharmaceuticals International, plc | $6.0B | 59.9 | 14.0 | 51.6 | 10.4 | 58.9 | 7 | BEARISH | 88.2 |
| SHPMY Shanghai Pharmaceuticals Holding Co., Ltd | $5.1B | 12.8 | 6.2 | 6.5 | 2.9 | 4.1 | 5 | BEARISH | -16.3 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 146.9 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 2.2 |
| OCPNF Olympus Corporation | $12B | 24.6 | 10.6 | 12.7 | 7.9 | 7.8 | 5 | BEARISH | -9.8 |
| GNNSF Genscript Biotech Corporation | $9.6B | -14.1 | -15.4 | 2.9 | -32.0 | 53.1 | 4 | BEARISH | 97.7 |
| ALNY Alnylam Pharmaceuticals, Inc. | $30B | 37.1 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -50.9 |
| MIRM Mirum Pharmaceuticals, Inc. | $5.2B | -5.7 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | BEARISH | 20.0 |
| SUPN Supernus Pharmaceuticals, Inc. | $2.4B | -20.9 | -10.5 | -12.6 | -26.6 | 24.9 | 3 | BEARISH | -21.6 |
| MDLN Medline Inc. | $30B | 38.5 | 3.2 | 4.4 | 0.8 | — | 4 | BEARISH | — |
| TWST Twist Bioscience Corporation | $9.2B | -69.7 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | BEARISH | 356.3 |
| LNTH Lantheus Holdings, Inc. | $6.5B | 23.8 | 22.2 | 17.1 | 19.3 | 2.3 | 5 | BEARISH | 76.8 |
| ABCL AbCellera Biologics Inc. | $3.8B | -23.0 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | BEARISH | 111.6 |
| NHC National HealthCare Corporation | $3.7B | 24.1 | 13.1 | 12.6 | 9.9 | 6.9 | 8 | BEARISH | 83.8 |
| CAMRF Camurus AB | $3.7B | 58.0 | 15.8 | 89.3 | 34.3 | -0.2 | 6 | BEARISH | -10.3 |
| RMYHY Ramsay Health Care Limited | $9.2B | 40.8 | 6.6 | 4.2 | 1.8 | 4.2 | 7 | BEARISH | 85.2 |
| DNTH Dianthus Therapeutics, Inc. | $4.3B | -615.5 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | BEARISH | 138.4 |
| HYPMY Hypera S.A. | $3.8B | 7.9 | 13.2 | 12.8 | 21.0 | 31.8 | 8 | BEARISH | -7.7 |
| RCUS Arcus Biosciences, Inc. | $2.3B | -4.5 | -89.2 | 309.6 | -222.0 | -55.3 | 0 | BEARISH | 5.8 |
| PRAX Praxis Precision Medicines, Inc. | $7.1B | -20.8 | -38.9 | -51.2 | — | -100.0 | 4 | BEARISH | 50.2 |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -20.6 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2279.1 |
| BEAM Beam Therapeutics Inc. | $2.5B | -29.1 | -8.1 | -184.5 | -25036.3 | 158.9 | 4 | BEARISH | -15.6 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.2 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 57.9 |
| IMVT Immunovant, Inc. | $5.9B | -10.1 | -80.1 | 707.5 | -2159.6 | — | 2 | BEARISH | 50.3 |
| DNLI Denali Therapeutics Inc. | $2.9B | -6.6 | -54.9 | -281.7 | -3539.2 | — | 3 | BEARISH | 17.5 |
| WUXAY WuXi AppTec Co., Ltd. | $68B | 15.4 | 30.2 | 35.4 | 39.1 | 25.0 | 8 | BEARISH | 85.4 |
| TEM Tempus AI, Inc. | $12B | -48.0 | -67.4 | -19.8 | 1.5 | 50.4 | 4 | BEARISH | -22.8 |
| TXG 10x Genomics, Inc. | $9.3B | -129.7 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | BEARISH | 446.1 |
| BLTE Belite Bio, Inc | $5.9B | -52.1 | -20.8 | -11.5 | — | — | 3 | BEARISH | 55.4 |
| CGON CG Oncology Inc. | $5.5B | -23.3 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | BEARISH | 46.6 |
| RTEZ Rest Ez Inc. | $4.2B | — | — | — | — | — | — | BEARISH | 0.0 |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.4B | -19.4 | -74.7 | 2020.5 | — | 100.0 | 5 | BEARISH | 89.3 |
| INCPF InnoCare Pharma Limited | $2.4B | 18.7 | 12.6 | 45.8 | 23.1 | 108.5 | 4 | BEARISH | -50.9 |
| DMPHF Dermapharm Holding SE | $2.4B | 13.8 | 25.6 | 13.0 | 8.1 | 0.5 | 5 | BEARISH | 20.6 |
| YPHDF Ypsomed Holding AG | $5.7B | 23.8 | 31.1 | 17.4 | 22.5 | -2.3 | 8 | BEARISH | -8.1 |
| VRBCF Virbac S.A. | $3.2B | 18.7 | 13.6 | 12.7 | 11.4 | 3.9 | 5 | BEARISH | 10.8 |
| MEDGF Medacta Group S.A. | $2.7B | 33.1 | 17.1 | 9.8 | 11.4 | 8.9 | 4 | BEARISH | 63.9 |
| ORPEF Emeis | $2.3B | -4.5 | -19.0 | 3.2 | -5.4 | 40.2 | 5 | BEARISH | 0.0 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.5 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 5.6 |
| MMED MiniMed Group, Inc. | $5.2B | — | — | — | — | — | — | BEARISH | — |
| VERA Vera Therapeutics, Inc. | $2.0B | -5.0 | -91.8 | 2030.6 | — | — | 1 | BEARISH | 0.3 |
| RVMD Revolution Medicines, Inc. | $40B | -20.6 | -79.1 | 186.4 | — | — | 1 | BEARISH | 243.7 |
| DXCM DexCom, Inc. | $29B | 30.4 | 38.5 | 42.9 | 19.0 | 15.5 | 9 | BEARISH | 10.6 |
| BNTX BioNTech SE | $22B | -11.4 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -17.1 |
| CORT Corcept Therapeutics Incorporated | $9.3B | 166.5 | 8.1 | 3.1 | 16.5 | 16.0 | 6 | BEARISH | 19.4 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.2 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 68.2 |
| HIMS Hims & Hers Health, Inc. | $6.2B | -45.5 | -32.0 | -7.1 | -11.5 | 28.0 | 4 | BEARISH | -43.1 |
| CRSP CRISPR Therapeutics AG | $4.8B | -10.4 | -26.1 | -253.2 | -895.3 | -62.7 | 3 | BEARISH | -27.1 |
| IDYA IDEAYA Biosciences, Inc. | $3.4B | -17.2 | -16.2 | -42.9 | -1269.6 | 3244.7 | 4 | BEARISH | 15.7 |
| TARS Tarsus Pharmaceuticals, Inc. | $3.2B | -64.8 | -13.7 | 268.1 | -10.7 | 105.2 | 5 | BEARISH | 2.5 |
| TLX Telix Pharmaceuticals Limited | $3.1B | 92.5 | 8.6 | -1.0 | 8.0 | 10.5 | 4 | BEARISH | -17.4 |
| MBX MBX Biosciences, Inc. Common Stock | $2.3B | -21.3 | -33.2 | 1634.0 | — | — | 2 | BEARISH | 211.8 |
| PGEN Precigen, Inc. | $2.2B | -5.4 | -4640.4 | -30.1 | 36.5 | 1875.0 | 5 | BEARISH | 42.1 |
| JAZZ Jazz Pharmaceuticals plc | $14B | 13.6 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 48.9 |
| MDGL Madrigal Pharmaceuticals, Inc. | $10B | -34.2 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | 3.3 |
| IBRX ImmunityBio, Inc. | $8.7B | -8.5 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 226.8 |
| TVTX Travere Therapeutics, Inc. | $4.7B | -110.7 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 77.5 |
| HAWPY Haw Par Corporation Limited | $3.0B | 12.3 | 5.2 | 1.6 | 93.0 | -12.8 | 4 | BEARISH | -20.4 |
| CHSYF China Medical System Holdings Limited | $2.7B | 13.6 | 8.6 | 9.0 | 21.9 | 9.2 | 4 | BEARISH | -17.8 |
| BRCTF BioArctic AB | $2.6B | 260.2 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BEARISH | -8.6 |
| HRMY Harmony Biosciences Holdings, Inc. | $2.1B | 11.9 | 20.5 | 35.7 | 28.9 | 24.3 | 5 | BEARISH | 24.4 |
| INSM Insmed Incorporated | $20B | -23.1 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -41.7 |
| GIKLY Grifols, S.A. | $15B | 15.9 | 8.4 | 7.4 | 8.2 | -0.2 | 6 | BEARISH | -19.0 |
| IONS Ionis Pharmaceuticals, Inc. | $7.1B | -12.5 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | BEARISH | -39.3 |
| REGMF RemeGen Co., Ltd. | $5.6B | 9.1 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | -16.4 |
| PTCT PTC Therapeutics, Inc. | $5.1B | -124.3 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | BEARISH | -8.6 |
| LABFF Laboratorios Farmaceuticos Rovi, S.A. | $3.4B | 17.0 | 29.3 | 19.6 | 39.1 | 3.3 | 6 | BEARISH | -25.9 |
| AMFPF Amplifon S.p.A. | $3.0B | 42.9 | 5.7 | 7.2 | 6.4 | -0.2 | 5 | BEARISH | -36.3 |
| PBLS Parabilis Medicines, Inc. | $3.0B | — | — | — | — | — | — | BEARISH | — |
| BKD Brookdale Senior Living Inc. | $2.4B | -16.5 | -362.1 | 10.3 | 3.2 | -2.3 | 6 | BEARISH | 11.9 |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | -9.1 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -46.2 |
| SMMT Summit Therapeutics Inc. | $12B | -13.2 | -192.5 | 1714.4 | — | — | 3 | BEARISH | -22.7 |
| SBMFF Sino Biopharmaceutical Limited | $12B | 30.4 | 21.1 | 40.0 | 17.7 | 28.2 | 7 | BEARISH | -28.2 |
| AXSM Axsome Therapeutics, Inc. | $7.6B | -38.5 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 13.4 |
| SFOSF Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | $5.8B | 17.8 | 10.7 | 6.3 | 8.4 | 53.9 | 7 | BEARISH | -34.2 |
| TRSBF 3SBio Inc. | $4.3B | 3.4 | 37.1 | 80.3 | 25.3 | 93.8 | 7 | BEARISH | -48.7 |
| VKTX Viking Therapeutics, Inc. | $3.1B | -5.3 | -88.9 | 495.6 | — | — | 1 | BEARISH | -28.6 |
| TMDX TransMedics Group, Inc. | $2.5B | 15.9 | 36.3 | 18.7 | 7.7 | 25.8 | 3 | BEARISH | -45.2 |
| ZLDPF Zealand Pharma A/S | $2.4B | 5.7 | 16.3 | 57.2 | 87.2 | -49.2 | 3 | BEARISH | -54.1 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
IOVA vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F